Literature DB >> 27335696

Pattern of cytokine (IL-6 and IL-10) level as inflammation and anti-inflammation mediator of multiple organ dysfunction syndrome (MODS) in polytrauma.

Heber Bombang Sapan1, Idrus Paturusi2, Irawan Jusuf3, Ilhamjaya Patellongi3, Muh Nasrum Massi4, Aryono Djuned Pusponegoro5, Syafrie Kamsul Arief6, Ibrahim Labeda7, Andi Asadul Islam7, Leo Rendy1, Mochammad Hatta8.   

Abstract

Massive injury remains the most common cause of death for productive age group globally. The current immune, inflammatory paradigm, based on an incomplete understanding of the functional integration of the complex host response, remains a major impediment to the development of effective innovative diagnostic and therapeutic effort. This study attempt to investigate the pattern of inflammatory and anti-inflammatory cytokines such as interleukin-6 and 10 (IL-6 and IL-10) and their interaction in severe injury condition with its major complication as multiple organ dysfunction syndrome (MODS) and failure (MOF) after polytrauma. This is multicenter study held at 4 academic Level-1 Trauma center included 54 polytrauma participants. Inclusion criteria were age between 16-60 years old, had new acute episode of polytrauma which defined as injury in ≥2 body region with Injury Severity Score (ISS) ≥16, and the presence of Systemic Inflammation Response Syndrome (SIRS). Serum level of IL-6 and IL-10 were taken on day 2, 3, and 5 after trauma. During hospitalization, samples were observed for the occurrence of MODS or MOF using Sequential Organ Failure Assessment (SOFA) and mortality rate were also noted. Participant were mostly male with mean of age of 35, 9 years old, endured polytrauma caused by traffic accident. Elevation of cytokines (IL-6, IL-10, and IL-6/IL-10 ratio) had directly proportional with MODS and mortality. Threshold level of compensation for severe trauma is IL-6 of 50 pg/mL and trauma load of ISS ≥30. Inflammation reaction greater than this threshold level would result in downhill level of IL-6, IL-10, or IL-6/IL-10 ratio which associated with poor outcome (MODS and death). The elevation of these cytokines level were represent as compensation/adaptive immune system and its fall represent decompensating/failure of immune system after severe trauma. The pattern of IL-6 and IL-10 after polytrauma represent immune system effort to restore homeostasis. Besides cytokines interaction, there must be other factors that contribute to mortality and poor outcome after major trauma. Further study is needed to investigate genomic variant or polymorphism related to trauma.

Entities:  

Keywords:  IL10; IL6; Multiple organ dysfunction syndrome; polytrauma

Year:  2016        PMID: 27335696      PMCID: PMC4913232     

Source DB:  PubMed          Journal:  Int J Burns Trauma        ISSN: 2160-2026


  13 in total

Review 1.  Systemic inflammatory response syndrome.

Authors:  M G Davies; P O Hagen
Journal:  Br J Surg       Date:  1997-07       Impact factor: 6.939

2.  Cytokine levels (IL-4, IL-6, IL-8 and TGFβ) as potential biomarkers of systemic inflammatory response in trauma patients.

Authors:  Gershon Volpin; Miri Cohen; Michael Assaf; Tamar Meir; Rina Katz; Shimon Pollack
Journal:  Int Orthop       Date:  2014-01-09       Impact factor: 3.075

3.  Intestinal permeability and cytokine inflammatory response in multiply injured patients.

Authors:  Alenka Spindler-Vesel; Branka Wraber; Irena Vovk; Lidija Kompan
Journal:  J Interferon Cytokine Res       Date:  2006-10       Impact factor: 2.607

4.  Application of SOFA score to trauma patients. Sequential Organ Failure Assessment.

Authors:  M Antonelli; R Moreno; J L Vincent; C L Sprung; A Mendoça; M Passariello; L Riccioni; J Osborn
Journal:  Intensive Care Med       Date:  1999-04       Impact factor: 17.440

Review 5.  Interleukin-6 in surgery, trauma, and critical care part II: clinical implications.

Authors:  Randeep S Jawa; Sergio Anillo; Kristin Huntoon; Heinz Baumann; Mahmoud Kulaylat
Journal:  J Intensive Care Med       Date:  2011 Mar-Apr       Impact factor: 3.510

6.  The definition of polytrauma: variable interrater versus intrarater agreement--a prospective international study among trauma surgeons.

Authors:  Nerida E Butcher; Natalie Enninghorst; Krisztian Sisak; Zsolt J Balogh
Journal:  J Trauma Acute Care Surg       Date:  2013-03       Impact factor: 3.313

Review 7.  Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS)

Authors:  R C Bone
Journal:  Ann Intern Med       Date:  1996-10-15       Impact factor: 25.391

8.  The early IL-6 and IL-10 response in trauma is correlated with injury severity and mortality.

Authors:  J Stensballe; M Christiansen; E Tønnesen; K Espersen; F K Lippert; L S Rasmussen
Journal:  Acta Anaesthesiol Scand       Date:  2009-04       Impact factor: 2.105

Review 9.  Pathophysiology of the systemic inflammatory response after major accidental trauma.

Authors:  Anne Craveiro Brøchner; Palle Toft
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2009-09-15       Impact factor: 2.953

10.  Systemic Inflammatory Response during Laparotomy.

Authors:  Ahmad Mahamid; Basel Jabarin; Gidon Almogy
Journal:  Int J Inflam       Date:  2014-08-05
View more
  21 in total

1.  Changes in expression of serum chemokine CXCL13 and IL-6 after hip replacement, and the relationship with lower limb vein thrombus.

Authors:  Zhiyu Guan
Journal:  Exp Ther Med       Date:  2019-12-20       Impact factor: 2.447

Review 2.  Immunoregulatory therapy strategies that target cytokine storms in patients with COVID-19 (Review).

Authors:  Xianyao Wang; Zhixu He; Xing Zhao
Journal:  Exp Ther Med       Date:  2021-02-03       Impact factor: 2.447

Review 3.  [Perioperative inflammation].

Authors:  J Rossaint; A Margraf; A Zarbock
Journal:  Anaesthesist       Date:  2019-07       Impact factor: 1.041

4.  The influence of surface modified poly(l-lactic acid) films on the differentiation of human monocytes into macrophages.

Authors:  Clara R Correia; Joana Gaifem; Mariana B Oliveira; Ricardo Silvestre; João F Mano
Journal:  Biomater Sci       Date:  2017-02-28       Impact factor: 6.843

Review 5.  Altered Offspring Immunity in Maternal Parasitic Infections.

Authors:  Lisa C Gibbs; Keke C Fairfax
Journal:  J Immunol       Date:  2022-01-15       Impact factor: 5.422

6.  Necroptosis as a potential therapeutic target in multiple organ dysfunction syndrome.

Authors:  Yao-Li Cui; Li-Hua Qiu; Shi-Yong Zhou; Lan-Fang Li; Zheng-Zi Qian; Xian-Ming Liu; Hui-Lai Zhang; Xiu-Bao Ren; Yong-Qiang Wang
Journal:  Oncotarget       Date:  2017-05-29

7.  Interleukin-6 and interleukin-10 plasma levels and mRNA expression in polytrauma patients.

Authors:  Heber B Sapan; Idrus Paturusi; Andi Asadul Islam; Irawan Yusuf; Ilhamjaya Patellongi; Muhammmad Nasrum Massi; Aryono D Pusponegoro; Syafrie K Arief; Ibrahim Labeda; Leo Rendy; Mochammad Hatta
Journal:  Chin J Traumatol       Date:  2017-11-04

8.  Study on relationship between elderly sarcopenia and inflammatory cytokine IL-6, anti-inflammatory cytokine IL-10.

Authors:  Yu-Dong Rong; Ai-Lin Bian; Hui-Ying Hu; Yue Ma; Xin-Zi Zhou
Journal:  BMC Geriatr       Date:  2018-12-12       Impact factor: 3.921

9.  Midkine Is Elevated After Multiple Trauma and Acts Directly on Human Cardiomyocytes by Altering Their Functionality and Metabolism.

Authors:  Ina Lackner; Birte Weber; Meike Baur; Melanie Haffner-Luntzer; Tim Eiseler; Giorgio Fois; Florian Gebhard; Borna Relja; Ingo Marzi; Roman Pfeifer; Sascha Halvachizadeh; Miriam Lipiski; Nikola Cesarovic; Hans-Christoph Pape; Miriam Kalbitz
Journal:  Front Immunol       Date:  2019-08-21       Impact factor: 7.561

10.  Intradialytic Complement Activation Precedes the Development of Cardiovascular Events in Hemodialysis Patients.

Authors:  Felix Poppelaars; Mariana Gaya da Costa; Bernardo Faria; Stefan P Berger; Solmaz Assa; Mohamed R Daha; José Osmar Medina Pestana; Willem J van Son; Casper F M Franssen; Marc A Seelen
Journal:  Front Immunol       Date:  2018-09-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.